Rotenone induces degeneration of photoreceptors and impairs the dopaminergic system in the rat retina

Neurobiology of Disease

Volumn 44, Issue 1, 2011, Pages 102-115

  Esteve Rudd, Julián ^a   Fernández Sánchez, Laura ^a   Lax, Pedro ^a   De Juan, Emilio ^a   Martín Nieto, José ^a   Cuenca, Nicolás ^a  

^a UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Dopaminergic neuron; Mitochondria; Parkinson disease; Pesticide; Photoreceptor; Retina; Retinal degeneration; Rotenone

Indexed keywords

PARVALBUMIN; ROTENONE; TYROSINE 3 MONOOXYGENASE;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B WAVE; CALCIUM CELL LEVEL; CELL LOSS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; IMMUNOREACTIVITY; NERVE DEGENERATION; NERVE ENDING; NERVE PLEXUS; NEUROTOXICITY; NIGHT VISION; NONHUMAN; OSCILLATORY POTENTIAL; PERIKARYON; PHOTOPIC VISION; PHOTORECEPTOR; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RAT; RETINA AMACRINE CELL; RETINA NERVE CELL; SYNAPTIC TRANSMISSION; TOXICITY TESTING; VISUAL IMPAIRMENT;

AMACRINE CELLS; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; DOPAMINERGIC NEURONS; ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; MITOCHONDRIA; NERVE DEGENERATION; NEUROTOXICITY SYNDROMES; PHOTORECEPTOR CELLS; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROTENONE; SYNAPSES; UNCOUPLING AGENTS;

EID: 79961128735     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.06.009     Document Type: Article

References (66)

1. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 2002, 136:317-324.
2. Archibald N.K., Clarke M.P., Mosimann U.P., Burn D.J. The retina in Parkinson's disease. Brain 2009, 132:1128-1145.
3. Barbato L., Rinalduzzi S., Laurenti M., Ruggieri S., Accornero N. Color VEPs in Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. 1994, 92:169-172.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
5. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 2006, 22:404-420.
6. Biehlmaier O., Alam M., Schmidt W.J. A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem. Int. 2007, 50:189-195.
7. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat. Disord. 2003, 9:S83-S89.
8. Bodis-Wollner I. Retinopathy in Parkinson disease. J. Neural Transm. 2009, 116:1493-1501.
9. Bodis-Wollner I., Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vision Res. 1998, 38:1479-1487.
10. Bové J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
11. Brandstätter J.H., Fletcher E.L., Garner C.C., Gundelfinger E.D., Wässle H. Differential expression of the presynaptic cytomatrix protein bassoon among ribbon synapses in the mammalian retina. Eur. J. Neurosci. 1999, 11:3683-3693.
12. Büeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp. Neurol. 2009, 218:235-246.
13. Casson R.J. Possible role of excitotoxicity in the pathogenesis of glaucoma. Clin. Exp. Ophthalmol. 2006, 34:54-63.
14. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
15. Chan C.S., Gertler T.S., Surmeier D.J. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 2009, 32:249-256.
16. Chen S.T., Hsu J.R., Hsu P.C., Chuang J.I. The retina as a novel in vivo model for studying the role of molecules of the Bcl-2 family in relation to MPTP neurotoxicity. Neurochem. Res. 2003, 28:805-814.
17. Cuenca N., Kolb H. Circuitry and role of substance P-immunoreactive neurons in the primate retina. J. Comp. Neurol. 1998, 393:439-456.
18. Cuenca N., De Juan J., Kolb H. Substance P-immunoreactive neurons in the human retina. J. Comp. Neurol. 1995, 356:491-504.
19. Cuenca N., Herrero M.T., Angulo A., De Juan E., Martínez-Navarrete G.C., López S., et al. Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease. J. Comp. Neurol. 2005, 493:261-273.
20. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
21. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
22. Davey G.P., Canevari L., Clark J.B. Threshold effects in synaptosomal and nonsynaptic mitochondria from hippocampal CA1 and paramedian neocortex brain regions. J. Neurochem. 1997, 69:2564-2570.
23. Delyfer M.N., Forster V., Neveux N., Picaud S., Léveillard T., Sahel J.A. Evidence for glutamate-mediated excitotoxic mechanisms during photoreceptor degeneration in the rd1 mouse retina. Mol. Vis. 2005, 11:688-696.
24. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996, 114:299-305.
25. Ellis C.J.K., Ikeda H. Evidence for retinal dopamine deficiency in Parkinson's disease. Dopaminergic Mechanisms in Vision 1988, 239-251. Alan R. Liss, New York. I. Bodis-Wollner, M. Piccolino (Eds.).
26. Esteve-Rudd J., Campello L., Herrero M.-T., Cuenca N., Martín-Nieto J. Expression in the mammalian retina of parkin and UCH-L1, two components of the ubiquitin-proteasome system. Brain Res. 2010, 1352:70-82.
27. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N Y Acad. Sci. 1992, 648:42-62.
28. Ghilardi M.F., Bodis-Wollner I., Onofrj M.C., Marx M.S., Glover A.A. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 1988, 111:131-149.
29. Gottlob I., Schneider E., Heider W., Skrandies W. Alteration of visual evoked potentials and electroretinograms in Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. 1987, 66:349-357.
30. Greenamyre J.T., Sherer T.B., Betarbet R., Panov A.V. Complex I and Parkinson's disease. IUBMB Life 2001, 52:135-141.
31. Hajee M.E., March W.F., Lazzaro D.R., Wolintz A.H., Shrier E.M., Glazman S., et al. Inner retinal layer thinning in Parkinson disease. Arch. Ophthalmol. 2009, 127:737-741.
32. Harnois C., Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 1990, 31:2473-2475.
33. Huoponen K. Leber hereditary optic neuropathy: clinical and molecular genetic findings. Neurogenetics 2001, 3:119-125.
34. Ikeda H., Head G.M., Ellis C.J. Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study. Vision Res. 1994, 34:2629-2638.
35. Inzelberg R., Ramirez J.A., Nisipeanu P., Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004, 44:2793-2797.
36. Johnson J.E., Perkins G.A., Giddabasappa A., Chaney S., Xiao W., White A.D., et al. Spatiotemporal regulation of ATP and Ca2+ dynamics in vertebrate rod and cone ribbon synapses. Mol. Vis. 2007, 13:887-919.
37. Kraft S.P., Parker J.A., Matuk Y., Rao A.V. The rat electroretinogram in combined zinc and vitamin A deficiency. Invest. Ophthalmol. Vis. Sci. 1987, 28:975-984.
38. Kupersmith M.J., Shakin E., Siegel I.M., Lieberman A. Visual system abnormalities in patients with Parkinson's disease. Arch. Neurol. 1982, 39:284-286.
39. Langheinrich T., Tebartz van Elst L., Lagrèze W.A., Bach M., Lücking C.H., Greenlee M.W. Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Clin. Neurophysiol. 2000, 111:66-74.
40. Mariani A.P., Neff N.H., Hadjiconstantinou M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment decreases dopamine and increases lipofuscin in mouse retina. Neurosci. Lett. 1986, 72:221-226.
41. Martínez-Navarrete G.C., Martín-Nieto J., Esteve-Rudd J., Angulo A., Cuenca N. α-Synuclein gene expression profile in the retina of vertebrates. Mol. Vis. 2007, 13:949-961.
42. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 1989, 163:1450-1455.
43. Nguyen-Legros J., Harnois C., Di Paolo I., Simon A. The retinal dopamine system in Parkinson's disease. Clin. Vis. Sci. 1993, 8:1-12.
44. Nicholls D.G. Oxidative stress and energy crises in neuronal dysfunction. Ann. N Y Acad. Sci. 2008, 1147:53-60.
45. Nightingale S., Mitchell K.W., Howe J.W. Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. J. Neurol. Neurosurg. Psychiatry 1986, 49:1280-1287.
46. Ogawa N., Asanuma M., Miyazaki I., Diaz-Corrales F.J., Miyoshi K. L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J. Neurol. 2005, 252:IV23-IV31.
47. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4:552-565.
48. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
49. Peppe A., Stanzione P., Pierantozzi M., Semprini R., Bassi A., Santilli A.M., et al. Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?. Electroencephalogr. Clin. Neurophysiol. 1998, 106:374-382.
50. Price M.J., Feldman R.G., Adelberg D., Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992, 42:887-890.
51. Schapira A.H. Human complex I defects in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1364:261-270.
52. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004, 318:215-224.
53. Semkova I., Huemmeke M., Ho M.S., Merkl B., Abari E., Paulsson M., et al. Retinal localization of the glutamate receptor GluR2 and GluR2-regulating proteins in diabetic rats. Exp. Eye Res. 2010, 90:244-253.
54. Sindhu K.M., Saravanan K.S., Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res. 2005, 1051:25-34.
55. Soós J., Engelhardt J.I., Siklós L., Havas L., Majtényi K. The expression of PARP, NF-ΚB and parvalbumin is increased in Parkinson disease. Neuroreport 2004, 15:1715-1718.
56. Stanzione P., Fattapposta F., Tagliati M., D'Alessio C., Marciani M.G., Foti A., et al. Dopaminergic pharmacological manipulations in normal humans confirm the specificity of the visual (PERG-VEP) and cognitive (P300) electrophysiological alterations in Parkinson's disease. Electroencephalogr. Clin. Neurophysiol. Suppl. 1990, 41:216-220.
57. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 1999, 55:659-665.
58. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007, 6:933-938.
59. Szikra T., Krizaj D. Intracellular organelles and calcium homeostasis in rods and cones. Vis. Neurosci. 2007, 24:733-743.
60. Tatton W.G., Kwan M.M., Verrier M.C., Seniuk N.A., Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 1990, 527:21-31.
61. Terzioglu M., Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 2008, 275:1384-1391.
62. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004, 318:225-241.
63. Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 2004, 10:S58-S62.
64. Witkovsky P. Dopamine and retinal function. Doc. Ophthalmol. 2004, 108:17-40.
65. Wong C., Ishibashi T., Tucker G., Hamasaki D. Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of parkinsonism. Exp. Eye Res. 1985, 40:509-519.
66. Yadava N., Nicholls D.G. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J. Neurosci. 2007, 27:7310-7317.